US OptionsDetailed Quotes

MYGN250516P32000

Watchlist

0.00
0.000.00%

15min DelayClose May 9 09:30 ET

0.00High0.00Low

Myriad Genetics Stock Discussion

Trytosaveabit

May 7 04:11

Not bad

$Myriad Genetics (MYGN.US)$ Guidance
Highlights
•First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.
•First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reduced coverage of GeneSight. MyRisk testing volume in the affected population grew 11% year-over-year.
•First quarter 2025 gross margin of 69...

Teddy123

Feb 24 22:00

Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio

$Myriad Genetics (MYGN.US)$
Can AI Transform Prostate Cancer Testing? Myriad Genetics' Latest Technology Promises 48-Hour Results

Teddy123

Feb 6 09:46

Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay

$Myriad Genetics (MYGN.US)$
Molecular Cancer Detection Breakthrough: Myriad Genetics Patents Game-Changing MRD Testing Methods

Teddy123

Feb 5 21:39

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

$Myriad Genetics (MYGN.US)$
Revolutionary Cancer Testing Integration: Myriad Genetics Slashes Result Times to Under 10 Days

905745367

Dec 6, 2024 23:01

$Myriad Genetics (MYGN.US)$ what happen to this stock?

Trytosaveabit

Mar 21, 2024 04:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1, 2024 22:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 31, 2024 06:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 19, 2024 07:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 2, 2024 20:32

The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.

Investors Aren't Buying Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues

No comment yet